Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of genomic signature in predicting baseline resistance to Nivolumab in advanced Non-small cell lung cancer

Next Previous
Trial Profile

Effect of genomic signature in predicting baseline resistance to Nivolumab in advanced Non-small cell lung cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Oct 2018 New trial record
    • 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top